

THE SEARLE COMPANY LIMITED  
One IBL Centre, 2nd Floor,  
Plot # 1. Block 7 & 8, D.M.C.H.S.,  
Tipu Sultan Road. Off Shahra-e-Faisal,  
Karachi Postal Code-75350  
UAN: (021) 111 SEARLE (732753)  
Tel: (92-21) 371 70 200, 370 70 201  
Fax: (92-21) 371 70 224, 371 70 225

**Dated:** September 1, 2025

**Ref:** C/PSX-M.Info.20250901-

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building,  
Karachi.

**SEARLE**

Dear Sir,

**Disclosure of Material Information**

In accordance with Section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following information:

Further to the disclosure of material information made by The Searle Company Limited (the "**Company**") on July 12, 2023, it is hereby informed that the Company has successfully obtained registration of **Denosumab injections 120mg and 60mg (biosimilar drugs)** from the Drug Regulatory Authority of Pakistan.

The Company, being the product registration holder in Pakistan, has been granted rights under a License Agreement by Mabwell Pharmaceuticals, China (the manufacturer) to market and sell these biosimilar drugs in Pakistan. Denosumab is a monoclonal antibody and to be used for the management of osteoporosis (60mg) and oncology care (120mg).

We are pleased to inform that the Company is now preparing for the commercial launch of Denosumab injections in Pakistan, marking a significant milestone in expanding its product portfolio.

This development reflects the Company's commitment to enhancing its product offerings and strengthening its business, thereby improving the quality of its earnings and creating greater value for shareholders.

You may please inform the TREC holders accordingly.

Yours truly,



Mudassir Habib Khan  
Company Secretary

✓